These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25029780)

  • 21. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-episode psychosis in a managed care setting: clinical management and research.
    Jarskog LF; Mattioli MA; Perkins DO; Lieberman JA
    Am J Psychiatry; 2000 Jun; 157(6):878-84. PubMed ID: 10831465
    [No Abstract]   [Full Text] [Related]  

  • 23. Improving treatment adherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2011 Sep; 72(9):e28. PubMed ID: 21951990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoeconomic factors related to the treatment of schizophrenia. Concluding discussion.
    J Clin Psychiatry; 1999; 60 Suppl 3():59-60. PubMed ID: 10073380
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
    Barnett PG; Scott JY; Krystal JH; Rosenheck RA;
    J Clin Psychiatry; 2012 May; 73(5):696-702. PubMed ID: 22697193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance of compliance and persistence measures in predicting clinical and economic outcomes using administrative data from German sickness funds.
    Frey S; Stargardt T
    Pharmacotherapy; 2012 Oct; 32(10):880-9. PubMed ID: 23033227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia.
    Dursun S
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):3-4. PubMed ID: 16144780
    [No Abstract]   [Full Text] [Related]  

  • 28. Improving antipsychotic adherence among patients with schizophrenia: savings for states.
    Predmore ZS; Mattke S; Horvitz-Lennon M
    Psychiatr Serv; 2015 Apr; 66(4):343-5. PubMed ID: 25555222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia.
    Lang K; Federico V; Muser E; Menzin J; Menzin J
    J Med Econ; 2013 Aug; 16(8):997-1006. PubMed ID: 23777223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system.
    Dassa D; Boyer L; Benoit M; Bourcet S; Raymondet P; Bottai T
    Aust N Z J Psychiatry; 2010 Oct; 44(10):921-8. PubMed ID: 20932206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuity of care after inpatient discharge of patients with schizophrenia in the Medicaid program: a retrospective longitudinal cohort analysis.
    Olfson M; Marcus SC; Doshi JA
    J Clin Psychiatry; 2010 Jul; 71(7):831-8. PubMed ID: 20441730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unbuckling the "chemical straitjacket": the legal significance of recent advances in the pharmacological treatment of psychosis.
    Mossman D
    San Diego Law Rev; 2002; 39(4):1033-164. PubMed ID: 15212045
    [No Abstract]   [Full Text] [Related]  

  • 33. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia.
    Chue P; Chue J
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):259-69. PubMed ID: 22812548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication.
    Citrome L
    Int J Clin Pract; 2010 Jan; 64(2):216-39. PubMed ID: 19886879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In brief: Injectable paliperidone palmitate for schizophrenia.
    Med Lett Drugs Ther; 2009 Nov; 51(1324):88. PubMed ID: 19890247
    [No Abstract]   [Full Text] [Related]  

  • 36. Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: a managed care perspective.
    Liu J
    Am J Manag Care; 2014 Jun; 20(8 Suppl):S174-83. PubMed ID: 25180707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical guideline recommendations for antipsychotic long-acting injections.
    Kane JM; Garcia-Ribera C
    Br J Psychiatry Suppl; 2009 Nov; 52():S63-7. PubMed ID: 19880920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics.
    Bera R; Offord S; Zubek D; Lau G; Lin J; Baker RA; Karson C
    J Med Econ; 2013; 16(4):522-8. PubMed ID: 23360177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacoeconomics of schizophrenia in the 21st century.
    Hanson MA
    J Clin Psychiatry; 1999; 60 Suppl 1():26-7; discussion 28-30. PubMed ID: 10037168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.